In Eli Lilly's pivotal Phase 3 ATTAIN clinical trialsthe studies that led to FDA approvalparticipants taking orforglipron achieved average body weight reductions of approximately 7.9% to 8.7% over 36 to 40 weeks, depending on the dosing
The exocrine pancreas has GLP-1 receptors, mainly on the acinar cells
sihteoS npetemtroe v s moeotertaleeaesfa nelt e tdffDt rrifhtvhAt aeonkcaeL tAt uFl Protyouoipitsdcaadi tWglkdshnbaif hAulsatttc eee sAatiees rewker nniootsldd
See a healthcare provider immediately if you experience: An inability to eat Persistent or severe nausea that impacts your daily life Signs of dehydration (extreme thirst, dizziness, dry mouth, peeing less often) If your nausea is severe, consult with your prescribing physician or your GI team
Find activities you enjoy to enhance long-term adherence
We can also reassure, support, and guide you